Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide

Elena Tourkina, Michael Bonner, Jim C. Oates, Ann F. Hofbauer, Mathieu Richard, Sergey L. Znoyko, Richard P. Visconti, Jing Zhang, Corey M. Hatfield, Richard M. Silver, Stanley HoffmanFibrogenesis 2011 · DOI

TL;DR

This study reveals that a deficiency in caveolin-1 in monocytes of scleroderma patients leads to their over-expression of CXCR4, causing hyper-migration into lung tissue and contributing to interstitial lung disease (ILD). A peptide that restores caveolin-1 function effectively reverses this hyper-migration and reduces fibrocyte accumulation in a mouse model, suggesting a potential therapeutic avenue for SSc-ILD.

What Problem Does This Paper Address?

Scleroderma (systemic sclerosis, SSc) is a complex autoimmune disease that often leads to interstitial lung disease (ILD), a major cause of mortality. While fibrocytes (monocyte-derived cells) are known to play a role in fibrotic diseases, the precise mechanisms by which they contribute to SSc-ILD have not been fully elucidated. Specifically, the paper addresses the gap in understanding how monocyte and fibrocyte behavior is altered in SSc-ILD and how these alterations contribute to the disease pathology. The researchers focus on the role of caveolin-1, a protein known to regulate cell signaling, and its potential link to the increased migration and accumulation of fibrocytes in the lungs of SSc patients.

Methods

The study employed a multi-pronged approach:

  • Immunohistochemistry: Lung tissue samples from SSc-ILD patients and healthy controls were stained to identify and quantify specific cell populations (fibrocytes and their precursors) using markers like CD45, CD34, CD14, Collagen I (ColI), and CXCR4.
  • Western Blot Analysis: This technique was used to compare the expression levels of CXCR4 in lung tissue from SSc-ILD patients and controls.
  • In Vitro Migration Assays (Micro-Boyden Chambers): Monocytes isolated from SSc-ILD patients and healthy individuals were tested for their migratory response to CXCL12 (a chemoattractant). The effect of a caveolin scaffolding domain (CSD) peptide, designed to restore caveolin-1 function, was also assessed. Additionally, normal monocytes were treated with TGF-β to mimic the SSc phenotype and then tested for migration with and without CSD peptide.
  • Flow Cytometry: Peripheral blood mononuclear cells (PBMCs) from SSc-ILD patients and controls were analyzed to characterize the phenotype of circulating monocytes and fibrocytes.
  • Animal Model (Bleomycin-induced lung fibrosis): Mice were treated with bleomycin to induce lung fibrosis, and the effect of CSD peptide treatment on fibrocyte accumulation in the lungs was evaluated using flow cytometry and immunohistochemistry.

Datasets

The study utilized human samples and an animal model:

  • Human Lung Tissue: Samples were obtained from seven SSc-ILD patients and four healthy individuals. Autopsy specimens were also used.
  • Human Peripheral Blood: Blood was collected from SSc-ILD patients and healthy donors for PBMC isolation.
  • Animal Model: Mice were used in a bleomycin-induced lung fibrosis model.

No new benchmarks were introduced; the study focused on characterizing cell populations and their behavior in existing models and patient samples.

Key Insights and Ideas

  • Caveolin-1 Deficiency Drives Monocyte Hyper-migration: The core finding is that SSc-ILD monocytes have reduced caveolin-1, leading to an upregulation of CXCR4. This CXCR4 overexpression makes them excessively migratory towards CXCL12, a key factor in their recruitment to the lungs.
  • CSD Peptide as a Functional Restorer: The caveolin scaffolding domain (CSD) peptide effectively counteracts the effects of caveolin-1 deficiency. It reverses the hyper-migration of SSc monocytes and significantly reduces fibrocyte accumulation in the lungs of a mouse model.
  • Fibrocytes are Abundant in SSc-ILD Lungs: The study confirmed the presence of fibrocytes (defined by markers like CD45/CD34/CXCR4 and Collagen I) in the lung tissue of SSc-ILD patients, but not in healthy individuals.
  • Phenotypic Differences in SSc Monocytes: SSc monocytes exhibit distinct characteristics, including higher expression of Collagen I, CD14, and CD34, suggesting they are more primed towards a fibrotic phenotype.
  • CXCL12/CXCR4 Axis is Central: The research strongly implicates the CXCL12/CXCR4 signaling pathway as a critical driver for monocyte and fibrocyte recruitment into damaged lung tissue in SSc-ILD.

Key Results

  • Increased Fibrocytes in SSc-ILD Lungs: CXCR4+/Coll+, CD34+/Coll+, and CD45+/Coll+ cells were significantly more prevalent in SSc-ILD lung tissue compared to controls. CXCR4+/Coll+ cells were the most abundant subset.
  • Upregulated CXCR4 and CXCL12: SSc-ILD lung tissue showed a more than fourfold increase in CXCR4 expression and significantly upregulated CXCL12 staining, particularly in epithelial cells and alveolar macrophages.
  • Sevenfold Increase in Monocyte Migration: SSc monocytes exhibited an almost sevenfold increase in migration towards CXCL12 compared to normal monocytes.
  • CSD Peptide Reverses Hyper-migration: CSD peptide treatment completely inhibited the migration of both SSc and normal monocytes in response to CXCL12.
  • TGF-β Mimics SSc Phenotype: TGF-β treatment induced a 15-fold increase in normal monocyte migration, which was also reversed by CSD peptide.
  • Distinct Monocyte Phenotypes in SSc Blood: SSc patients showed a higher percentage of CD14+ monocytes and increased prevalence of CD14+/Coll+, CD14+/CD34+/Coll+, and CD14-/CD34+/Coll+ cells in their peripheral blood.
  • Reduced Fibrocyte Accumulation in Mice: CSD peptide treatment significantly inhibited the bleomycin-induced accumulation of CD45+/Coll+ fibrocytes in mouse lungs by approximately 75%.

Limitations and Future Work

  • Fibrocyte Definition Ambiguity: The authors acknowledge that the precise definition of fibrocytes and related cell types (like collagen-producing monocytes) can be ambiguous, making direct comparisons with other studies challenging.
  • In Vitro vs. In Vivo Fibrocyte Migration: The study was limited in its ability to perform migration experiments with in vitro-differentiated normal and SSc-ILD fibrocytes due to complexities in starting PBMC populations.
  • Therapeutic Potential: The study strongly suggests the potential of CSD peptide as a therapeutic agent for fibrotic lung diseases like SSc-ILD by inhibiting fibrocyte differentiation and migration. Future work would likely involve further preclinical and clinical trials to validate this therapeutic potential.
  • Mechanistic Details: While the study highlights the role of caveolin-1 and CXCR4, further research could delve deeper into the specific signaling pathways regulated by caveolin-1 in monocytes and how their loss directly impacts CXCR4 expression and subsequent migration.

Summary updated

Abstract

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in scleroderma (systemic sclerosis, or SSc). Fibrocytes are a monocyte-derived cell population implicated in the pathogenesis of fibrosing disorders. Given the recently recognized importance of caveolin-1 in regulating function and signaling in SSc monocytes, in the present study we examined the role of caveolin-1 in the migration and/or trafficking and phenotype of monocytes and fibrocytes in fibrotic lung disease in human patients and an animal model. These studies fill a gap in our understanding of how monocytes and fibrocytes contribute to SSc-ILD pathology. We found that C-X-C chemokine receptor type 4-positive (CXCR4+)/collagen I-positive (ColI+), CD34+/ColI+ and CD45+/ColI+ cells are present in SSc-ILD lungs, but not in control lungs, with CXCR4+ cells being most prevalent. Expression of CXCR4 and its ligand, stromal cell-derived factor 1 (CXCL12), are also highly upregulated in SSc-ILD lung tissue. SSc monocytes, which lack caveolin-1 and therefore overexpress CXCR4, exhibit almost sevenfold increased migration toward CXCL12 compared to control monocytes. Restoration of caveolin-1 function by administering the caveolin scaffolding domain (CSD) peptide reverses this hypermigration. Similarly, transforming growth factor β-treated normal monocytes lose caveolin-1, overexpress CXCR4 and exhibit 15-fold increased monocyte migration that is CSD peptide-sensitive. SSc monocytes exhibit a different phenotype than normal monocytes, expressing high levels of ColI, CD14 and CD34. Because ColI+/CD14+ cells are prevalent in SSc blood, we looked for such cells in lung tissue and confirmed their presence in SSc-ILD lungs but not in normal lungs. Finally, in the bleomycin model of lung fibrosis, we show that CSD peptide diminishes fibrocyte accumulation in the lungs. Our results suggest that low caveolin-1 in SSc monocytes contributes to ILD via effects on cell migration and phenotype and that the hyperaccumulation of fibrocytes in SSc-ILD may result from the altered phenotype and migratory activity of their monocyte precursors.
BibTeX
@inproceedings{tourkina2011altered,
  author = {Elena Tourkina and Michael Bonner and Jim C. Oates and Ann F. Hofbauer and Mathieu Richard and Sergey L. Znoyko and Richard P. Visconti and Jing Zhang and Corey M. Hatfield and Richard M. Silver and Stanley Hoffman},
  title = {{Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide}},
  booktitle = {Fibrogenesis},
  year = {2011},
  doi = {10.1186/1755-1536-4-15},
}
Figure